Diane Harper, MD, MPH, MS
MD University of Kansas, Kansas City, KS
SB Massachusetts Institute of Technology, Cambridge, MA
SM Massachusetts Institute of Technology, Cambridge, MA
MPH University of Kansas, Kansas City, KS with Health Economics emphasis Stanford University, Palo Alto, CA
Diane Harper, MD, MPH, MS is an internationally known researcher, clinician and educator in the field of HPV associated diseases, especially focused on the prevention of cervical cancer. She contributed to the sentinel research in designing and implementing the studies of both HPV vaccines, Cervarix and Gardasil, worldwide. She completed her undergraduate and graduate degrees at the Massachusetts Institute of Technology; her medical degree and residencies in Ob/Gyn and Family Medicine from the University of Kansas; and she attended Stanford University, studying Medical Decision Making/Cost Effectiveness Analysis as part of her Master of Public Health thesis.
Students who can bring mature backgrounds in other fields to the question of cancer screening and musculoskeletal fitness are most welcome.
Harper DM, Noll WW, Belloni DR, Cole BF. Randomized Clinical Trial of PCR Determined HPV Detection Methods: Self-Sampling vs. Clinician-Directed -- Biological Concordance and Womens Preferences. Am J Obstet Gynec 186:365-373, 2002.
Harper DM, Noll WW, Raymond R, Duncan LT, Belloni DR, Cole BF. Tampon samplings with longer cervico-vaginal cell exposures are equivalent to two consecutive swabs for the detection of high-risk HPV. Sexually Transmitted Diseases 29: 628-636, 2002.
Harper DM, Raymond M, Noll WW, Belloni DR, Cole BF. Factors affecting the detection rate of human papillomavirus. Ann Fam Med 1: 221-7, 2003.
Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, Carvalho N, Rotelli C, Teixeira J, Blatter M, Korn A, Quint Wim, Dubin G for the GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364: 1757-65, 2004.
Harper DM, Franco EL, Wheeler CM, Moscicki A-B, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G on behalf of the HPV Vaccine Study Group. Sustained Efficacy up to 4.5 years of a bivalent L1 virus like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised controlled trial. Lancet 2006;367:1247-55.
Garland S, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GWK, Ferris DG, Steben M, Bryan J, Taddeo F, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, and Koutsky LA, for the FUTURE I Investigators. Efficacy of a quadrivalent HPV (Types 6/11/16/18) L1 VLP Vaccine against external anogenital, vaginal, and cervical disease. A randomized controlled trial. NewEngl J Medicine. 2007: 356(19):1928-43.
Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GWK, Ferris DG, Steben M, Jones RW, Bryan J, Taddeo FJ, Bautista OM, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Paavonen J. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6/11/16/18) L1 virus like particle vaccine against high-grade vulval and vaginal lesions: A combined analysis of three clinical trials. Lancet 2007.
Cutts FT, Franceschi S, Goldie S, Castellsague X, de Sanjose S, Garnett G, Edmunds WJ, Claeys P, Goldenthal K, Harper DM, Markowitz L. Human Papillomavirus and HPV vaccines: a review. Bulletin of the World Health Organization. 85(9):719-26, 2007 Sep.
Harper DM. Preliminary HPV vaccine results for women older than 25 years. Lancet. 2009:373: 1921-1922.